Stunning Start For Vertex Cystic Fibrosis Triple Combo
Trikafta Shatters Forecasts With Q4 $420m Sales
Executive Summary
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
You may also be interested in...
Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
At Last: Vertex Strikes CF Deal In England
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.
Vertex Strikes Spanish Payment-For-Results CF Deal
Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.
Need a specific report? 1000+ reports available
Buy Reports